Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor-positive metastatic breast cancer in Canada.
about
Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom.Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in CanadaCost-utility analyses of drug therapies in breast cancer: a systematic review.Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancerPalbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada.
P2860
Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor-positive metastatic breast cancer in Canada.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness of lapatini ...... tatic breast cancer in Canada.
@en
Cost-effectiveness of lapatini ...... tatic breast cancer in Canada.
@nl
type
label
Cost-effectiveness of lapatini ...... tatic breast cancer in Canada.
@en
Cost-effectiveness of lapatini ...... tatic breast cancer in Canada.
@nl
prefLabel
Cost-effectiveness of lapatini ...... tatic breast cancer in Canada.
@en
Cost-effectiveness of lapatini ...... tatic breast cancer in Canada.
@nl
P2093
P2860
P356
P1433
P1476
Cost-effectiveness of lapatini ...... tatic breast cancer in Canada.
@en
P2093
P2860
P304
P356
10.3747/CO.20.1394
P577
2013-10-01T00:00:00Z